List of Excipients in Branded Drug RHINOCORT AQUA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	RHINOCORT AQUA	budesonide	54868-4411	ANHYDROUS DEXTROSE
Physicians Total Care Inc	RHINOCORT AQUA	budesonide	54868-4411	CARBOXYMETHYLCELLULOSE SODIUM
Physicians Total Care Inc	RHINOCORT AQUA	budesonide	54868-4411	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	RHINOCORT AQUA	budesonide	54868-4411	EDETATE DISODIUM
Physicians Total Care Inc	RHINOCORT AQUA	budesonide	54868-4411	HYDROCHLORIC ACID
Physicians Total Care Inc	RHINOCORT AQUA	budesonide	54868-4411	POLYSORBATE 80
Physicians Total Care Inc	RHINOCORT AQUA	budesonide	54868-4411	POTASSIUM SORBATE

Rhinocort Aqua Excipient Strategy and Commercial Opportunities

Last updated: October 6, 2026

Rhinocort Aqua is an aqueous, multidose nasal suspension containing budesonide at 32 mcg per spray. Its excipient system is designed to suspend micronized drug, support nasal deposition, control microbial growth, and maintain physical stability. The principal commercial opportunities are preservative-free delivery, improved sensory performance, device-led differentiation, private-label manufacturing, and regional reformulation.

What excipients are used in Rhinocort Aqua?

Rhinocort Aqua uses a conventional suspension platform rather than a solution formulation. The FDA labeling identifies the following inactive ingredients: microcrystalline cellulose, carboxymethylcellulose sodium, dextrose, polysorbate 80, disodium edetate, potassium sorbate, hydrochloric acid, and purified water.[1]

Excipient	Primary formulation function	Commercial relevance
Microcrystalline cellulose	Suspension matrix and viscosity modifier	Controls sedimentation and supports dose uniformity
Carboxymethylcellulose sodium	Suspending and rheology agent	Influences sprayability, redispersibility, and nasal residence
Dextrose	Tonicity and formulation adjustment	Affects comfort and osmolarity
Polysorbate 80	Wetting and dispersion aid	Helps distribute hydrophobic micronized budesonide
Disodium edetate	Chelating agent	Supports preservative performance and chemical stability
Potassium sorbate	Antimicrobial preservative	Enables multidose container use
Hydrochloric acid	pH adjustment	Controls product stability and tolerability
Purified water	Vehicle	Main continuous phase

The formulation is described as a suspension, so the excipients must maintain consistent redispersion and delivered-dose performance throughout the product’s shelf life. A generic or reformulated product cannot rely only on matching the ingredient list. It must demonstrate comparable spray performance, particle-size distribution, delivered dose, microbiological quality, and in-use stability.

How does the Rhinocort Aqua suspension system work?

The formulation uses microcrystalline cellulose and carboxymethylcellulose sodium as a structured vehicle. This combination creates enough viscosity and yield stress to keep micronized budesonide suspended while permitting atomization through the nasal pump.

The design creates a tradeoff:

• Higher viscosity can reduce sedimentation but may increase actuation force and impair plume formation.
• Lower viscosity can improve sprayability but may increase settling and dose variability.
• More surfactant can improve wetting but may increase foaming, taste, or mucosal irritation.
• More preservative can improve microbial control but may affect tolerability.
• A tighter particle-size distribution can improve dose consistency but may increase milling and characterization costs.

The formulation therefore depends on the interaction between the excipient system and the pump. A change in cellulose grade, polysorbate concentration, or micronized budesonide surface properties can alter plume geometry, droplet-size distribution, nasal deposition, and the amount of drug reaching the throat.

What commercial opportunities exist in Rhinocort Aqua excipients?

The strongest opportunities are not likely to come from substituting one commodity excipient for another. They are more likely to come from improving the relationship between excipients, formulation, and delivery device.

Preservative-free multidose nasal spray

Potassium sorbate is used to support microbial control in the multidose product. A preservative-free version could target patients who experience nasal irritation, dryness, or sensitivity to preservatives.

Potential platforms include:

• A sealed multidose pump with an airless pathway
• A bag-on-valve or mechanically isolated container
• A one-way valve system that limits microbial ingress
• Unit-dose or metered single-use packaging
• A device with reduced residual product and limited backflow

The commercial advantage would be strongest if a preservative-free product also improves sensory performance. A preservative-free version that retains the same throat drip, aftertaste, or pump force would have less differentiation.

The regulatory burden would shift from preservative effectiveness toward container-closure integrity, microbial ingress studies, in-use microbiological testing, and device reliability.

Low-irritation and improved sensory formulations

Nasal products compete partly on local tolerability. Excipient optimization can target:

• Reduced throat drip
• Lower aftertaste
• Less burning or stinging
• Lower nasal dryness
• Reduced foaming
• Easier actuation
• More consistent plume geometry

Dextrose, pH, ionic strength, surfactant level, and polymer concentration all affect sensory performance. The formulation should be optimized with human sensory testing and objective spray characterization rather than relying only on conventional stability data.

A low-irritation formulation could support premium OTC positioning, pediatric use, and patients who discontinue intranasal corticosteroids because of local discomfort.

Device-formulation integration

Rhinocort Aqua is a suspension, which makes the pump a critical part of product performance. Commercially valuable improvements may include:

• Improved redispersion after storage
• Reduced need for shaking
• More consistent first-dose delivery
• Better performance at low remaining fill volume
• Lower actuation force
• Dose counters
• Child-resistant or senior-friendly packaging
• Reduced environmental packaging weight

Device patents may provide more durable differentiation than excipient substitutions. A new product could use substantially similar active and inactive ingredients while obtaining protection around the pump, valve, container, dose-counting mechanism, or manufacturing process.

What formulations are protected by Rhinocort Aqua patents?

The original Rhinocort Aqua product was developed under AstraZeneca’s budesonide nasal-spray franchise. The principal commercial protection for the original product was based on product, formulation, and regulatory exclusivity associated with the branded nasal suspension.

The original US product patents and exclusivity periods are no longer the primary barrier to generic competition. The commercial protection available today is more likely to arise from:

1. New preservative-free formulations.
2. Improved suspension systems.
3. Device and container-closure configurations.
4. Pediatric or other method-of-use claims.
5. Manufacturing processes that improve particle-size control or dose uniformity.
6. New combinations with nasal moisturizing or barrier-support ingredients.

An excipient patent would need meaningful technical differentiation. A patent claiming only the use of a standard cellulose polymer, polysorbate 80, or potassium sorbate at routine concentrations would face substantial validity and obviousness risk.

More defensible claim strategies could cover:

• A defined polymer ratio linked to improved redispersion.
• A narrow particle-size distribution of micronized budesonide.
• A formulation with specified viscosity, yield stress, and sedimentation behavior.
• A preservative-free container system with demonstrated microbial protection.
• A defined spray plume and droplet-size profile.
• A formulation-device combination that produces improved nasal deposition.
• A manufacturing sequence that reduces agglomeration or improves content uniformity.

What is the FDA regulatory status of Rhinocort Aqua?

Rhinocort Allergy is an OTC nasal spray containing budesonide 32 mcg per spray. The product was switched from prescription to OTC status in the United States, and the current OTC labeling is directed to temporary relief of symptoms associated with hay fever or other respiratory allergies.[1,2]

Regulatory issue	Rhinocort Aqua commercial implication
Active ingredient	Budesonide
Route	Intranasal
Dosage form	Aqueous nasal suspension
Strength	32 mcg per spray
US status	OTC nasal allergy product
Reference framework	FDA OTC labeling and applicable nasal corticosteroid requirements
Biosimilar pathway	Not applicable; budesonide is a small molecule
Generic pathway	ANDA or applicable OTC route, depending on product and regulatory strategy
Main CMC burden	Suspension uniformity, spray performance, microbiology, stability, device compatibility

A reformulated product with the same active ingredient and indication could require an abbreviated application if it is positioned as a generic equivalent. A materially different delivery system, preservative-free architecture, or indication may require a different regulatory strategy.

The OTC status expands the commercial market but raises branding and consumer-experience requirements. A manufacturer must compete in pharmacy shelves, retailer search rankings, private-label channels, and seasonal allergy promotions.

What is the Orange Book status of Rhinocort Aqua?

The Orange Book is most relevant to prescription products approved under an NDA. OTC products marketed under an OTC monograph or an OTC switch framework do not create the same type of Orange Book patent barrier as a currently protected prescription product.[3]

For Rhinocort Aqua, the original patent estate should be treated as expired or commercially weak relative to newer formulation and device patents. The practical entry barriers are:

• FDA product and labeling requirements
• Demonstration of comparable delivered-dose performance
• Nasal pump qualification
• Manufacturing scale-up
• Seasonal inventory planning
• Retail distribution
• Brand recognition
• Consumer switching behavior

A prospective entrant should not assume that the absence of a blocking Orange Book patent eliminates all IP risk. Relevant patent searches should cover later patents assigned to the brand owner, device suppliers, contract manufacturers, and companies developing preservative-free intranasal systems.

When does Rhinocort Aqua lose exclusivity?

The original branded exclusivity has already expired for commercial purposes. Rhinocort’s present market position depends on brand equity, OTC distribution, product availability, and formulation execution rather than an active basic budesonide exclusivity period.

There is no biosimilar exclusivity issue because budesonide is a chemically synthesized small molecule. The relevant competitive risks are generic, private-label, authorized-generic, and line-extension products.

Generic launch scenarios

Scenario	Product profile	Commercial risk to Rhinocort
Basic generic	Budesonide 32 mcg nasal suspension	High price pressure
Retail private label	Same or substantially equivalent OTC product	High shelf and search visibility pressure
Preservative-free generic	Similar efficacy with improved tolerability claim	Moderate to high switching risk
Premium device product	Better pump, dose counter, or low-force actuation	Moderate brand erosion
Combination product	Budesonide with another nasal or allergy active	Potential category expansion
Pediatric-focused product	Age-specific delivery and packaging	Targeted share capture

Are Paragraph IV challenges relevant to Rhinocort Aqua?

Paragraph IV litigation is principally relevant to an ANDA applicant challenging an unexpired patent listed for an NDA product. The original Rhinocort Aqua market has moved beyond the main period in which Paragraph IV litigation would determine first generic entry.

A later Paragraph IV risk could arise if a patent holder lists a qualifying new patent covering a reformulated product, device, or method of use. The risk would depend on whether the patent is properly listable, whether the ANDA product is subject to the claim, and whether the applicant provides a valid certification.

For an acquirer or licensee, the relevant diligence questions are:

• Are any patents listed against the specific reference product?
• Are later formulation or device patents enforceable?
• Has any ANDA applicant filed a Paragraph IV certification?
• Are there pending settlements or launch restrictions?
• Does the proposed product use the same pump and container system?
• Is the product marketed under the OTC monograph, an NDA, or an ANDA?

No current biosimilar challenge pathway applies.

How strong is the Rhinocort Aqua patent estate?

The legacy patent estate is weak as a standalone barrier to entry because the core budesonide nasal-suspension technology is mature and the primary exclusivity period has passed.

Patent strength can still be created around a new product architecture. The strongest potential claims would combine measurable technical parameters with clinical or usability benefits.

Patent subject	Expected strength
Budesonide as an intranasal corticosteroid	Low; mature technology
Standard cellulose suspension system	Low to moderate
Conventional potassium sorbate preservation	Low
Defined rheology and particle-size profile	Moderate
Preservative-free multidose delivery	Moderate to strong if technically demonstrated
Improved device and suspension combination	Moderate to strong
New method of use	Dependent on claim scope and clinical evidence
Manufacturing process for dose uniformity	Moderate if difficult to design around

Patent claims should be supported by comparative data against the original formulation. Useful evidence includes sedimentation rates, redispersion time, dose uniformity through container life, plume geometry, droplet-size distribution, microbial ingress results, nasal irritation scores, and pharmacokinetic or deposition data where relevant.

Which companies could challenge or compete with Rhinocort Aqua?

Competition comes from branded and generic intranasal corticosteroids, not only budesonide products.

Product or category	Active ingredient	Competitive relevance
Rhinocort Allergy	Budesonide	Reference brand and direct product
Flonase Allergy Relief	Fluticasone propionate	Major OTC intranasal corticosteroid competitor
Flonase Sensimist	Fluticasone furoate	Premium sensory and device positioning
Nasacort Allergy 24HR	Triamcinolone acetonide	OTC corticosteroid competitor
Nasonex	Mometasone furoate	Prescription and OTC-category relevance
Store-brand nasal steroids	Various	Price and retailer penetration
Intranasal antihistamines	Azelastine and others	Alternative symptom-control category

The most direct competitors are manufacturers with established OTC allergy distribution, private-label supply contracts, and nasal-pump manufacturing capabilities. Contract development and manufacturing organizations can also become competitive threats if they offer ready-to-file suspension platforms.

What licensing opportunities exist for Rhinocort Aqua excipients and delivery technology?

Licensing value is strongest in four areas.

Excipient platform licensing

A supplier with a proprietary cellulose blend, redispersible suspension system, or low-irritation polymer platform could license the technology to generic or OTC manufacturers. The platform must offer measurable advantages over standard microcrystalline cellulose and carboxymethylcellulose sodium.

Preservative-free device licensing

A validated multidose preservative-free pump could support several nasal products, including corticosteroids, antihistamines, and saline systems. A platform license would be more valuable than a product-specific agreement if the device can be used across viscosities and suspension types.

Private-label supply

Retailers may seek budesonide nasal sprays with:

• Competitive cost per dose
• Reliable seasonal supply
• Retailer-specific packaging
• Flexible minimum order quantities
• Multi-country regulatory support
• Stable device sourcing

The most attractive supplier position combines formulation, filling, pump assembly, and regulatory documentation.

Regional commercialization

Markets outside the United States may permit different labeling, pack sizes, preservatives, or device configurations. A regional partner can adapt the formulation to local pharmacy channels and regulatory requirements while preserving the core budesonide suspension platform.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barriers are technical rather than molecule-specific.

Critical process controls include:

• Micronization and particle-size distribution
• Prevention of agglomeration
• Uniform wetting of budesonide
• Controlled polymer hydration
• Homogeneous bulk suspension
• Filling accuracy
• Pump priming and repriming
• Container-closure integrity
• Microbiological control
• Stability after repeated use

The manufacturing process should be designed around the final spray performance, not only bulk assay. A product can meet potency specifications and still fail on delivered dose, plume geometry, or user experience.

The highest-value IP opportunity is a formulation-device-manufacturing package that produces a demonstrated advantage and is difficult to reproduce with routine substitutions.

How does Rhinocort Aqua compare with competing nasal corticosteroids?

Rhinocort’s main differentiation is budesonide, an established intranasal corticosteroid with broad allergy use and strong consumer recognition. Its excipient system is conventional, which supports manufacturing feasibility but limits differentiation unless paired with a better device or new sensory profile.

Attribute	Rhinocort Aqua	Premium opportunity
Active ingredient	Budesonide	Retain established clinical identity
Formulation	Aqueous suspension	Improve redispersion and plume consistency
Preservative	Potassium sorbate	Develop preservative-free multidose format
Vehicle	Cellulose-based	Optimize comfort and throat-drip profile
Device	Metered nasal pump	Add dose counter and low-force actuation
Market	OTC allergy	Expand into private label and regional channels
IP position	Legacy protection largely expired	Build new formulation-device claims

Key Takeaways

1. Rhinocort Aqua uses a mature budesonide suspension platform built around microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, potassium sorbate, EDTA, dextrose, hydrochloric acid, and purified water.

2. The original exclusivity period is no longer the principal commercial barrier. Generic and private-label entry risk is substantial.

3. The best excipient opportunity is a measurable improvement in redispersion, spray consistency, sensory performance, or preservative-free delivery.

4. Device-formulation combination patents are likely to offer stronger protection than claims covering standard excipients alone.

5. Rhinocort has no biosimilar risk. Its relevant competitors are generic budesonide products, OTC nasal corticosteroids, private-label manufacturers, and premium delivery systems.

6. Commercial value is concentrated in preservative-free multidose technology, low-irritation formulations, improved nasal pumps, retailer supply, and regional licensing.

FAQs

Can Rhinocort Aqua be reformulated without potassium sorbate?

Yes. A reformulation could use a preservative-free multidose container or a unit-dose package. The product would need evidence for microbial control, container-closure integrity, in-use stability, and consistent dose delivery.

Which excipient is most important for Rhinocort Aqua dose uniformity?

The microcrystalline cellulose and carboxymethylcellulose sodium suspension system is central to dose uniformity because it controls sedimentation and redispersion. Pump performance and budesonide particle-size distribution are also critical.

Is a budesonide nasal spray eligible for biosimilar approval?

No. Budesonide is a small-molecule drug. A competing product would generally use a generic or applicable OTC regulatory pathway rather than the biosimilar pathway.

Can a new excipient create a patentable Rhinocort follow-on product?

Potentially, but the strongest patent case would require a defined formulation or formulation-device combination linked to a demonstrated technical benefit. Routine replacement of one compendial excipient with another would face greater patentability risk.

What is the most attractive commercial niche for a Rhinocort follow-on product?

A preservative-free, low-irritation, multidose nasal spray with a low-force pump, dose counter, and improved throat-drip profile offers the clearest premium positioning against conventional generic and private-label products.

References

1. DailyMed. (2024). Rhinocort Allergy: Budesonide nasal spray, suspension, 32 mcg per spray. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2009). FDA approves Rhinocort Aqua for over-the-counter use. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

4. U.S. Food and Drug Administration. (1999). Rhinocort Aqua NDA 020746 approval materials. FDA Drugs@FDA.

5. U.S. Food and Drug Administration. (2020). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. FDA.